ClinicalTrials.gg
CompletedNCT01199081ARTEMIS AF LTUpdated Jun 7, 2013

Pharmacokinetics and Optimal Timing of Dronedarone Initiation Following Long-term Amiodarone in Patients With Paroxysmal or Persistent Atrial Fibrillation

A Phase 4 interventional study of Dronedarone in Atrial Fibrillation, sponsored by Sanofi. Completed at 40 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-06-07.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing dronedarone in Atrial Fibrillation — 2 open to participants now, 2 under way, none of them phase 3. Dronedarone · Atrial Fibrillation.

Enrollment
14th of 26
154 · median 164
Started
2010
with 8 others
Phase 4
11 of 26
2 open now
Registered
13th of 26
by date
Lead sponsor
13 of 26
Sanofi

Among the 26 studies testing dronedarone in Atrial Fibrillation, this one is the 14th largest by enrollment, is one of 9 that started in 2010, is one of 11 in phase 4, and was the 13th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

2 of the 26 studies testing dronedarone in Atrial Fibrillation are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About dronedarone

Dronedarone: first FDA approval 2009 (MULTAQ), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing dronedarone in Atrial Fibrillation, or all of them as a file.
02

Study summary

Primary Objective:

  • Explore Dronedarone and active metabolite pharmacokinetic (PK) profiles according to different timings of Dronedarone initiation.

Secondary Objective:

  • Explore potential PK interaction between Dronedarone and Amiodarone
  • Evaluate the rate of Atrial Fibrillation (AF) recurrence during the study period (from randomization up to 60 days after)
  • To assess the safety of the change from Amiodarone to Dronedarone and Dronedarone safety
Read the detailed description

The maximum study duration per patient is 10 weeks

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Screening:

  • Paroxysmal or persistent AF having received at least 6 months of amiodarone before screening with at least the last 2 months at a regimen of 200 mg/day (during at least 5 days per week) prior to screening
  • Requiring a change from amiodarone treatment whatever the reason, but without liver, lung or thyroid toxicity related to previous use of amiodarone
  • At least one cardiovascular risk factor (i.e. age > 70, hypertension, diabetes, prior cerebrovascular disease or left atrial diameter >= 50 mm
  • Effective anticoagulation treatments verified by (INR) (target INR > 2)
  • Bazett \< 500 ms on 12-lead

Randomization:

  • Outpatients and Inpatients (except patients hospitalized during screening period for SAE)
  • Sinus rhythm
  • Effective oral anticoagulation treatment verified by INR (target INR > 2). INR should be closely monitored after initiating dronedarone in patients taking vitamin K antagonist as per their label
  • QTc Bazett \< 500 ms and PR \< 280 ms on 12-lead ECG

Exclusion criteria

Exclusion criteria:

Screening:

  • to oral anticoagulation
  • Acute condition known to cause AF
  • Permanent AF
  • Bradycardia \< 50 bpm at rest on the 12-lead
  • History of, or current heart failure or left ventricular systolic dysfunction
  • Unstable hemodynamic conditions
  • Severe hepatic impairment
  • Wolff-Parkinson-White Syndrome
  • Previous catheter ablation for atrial fibrillation or catheter ablation scheduled in the next 10 weeks
  • Previous history of Amiodarone intolerance or toxicity
  • History of thyroid dysfunction
  • Mandatory contraindicated concomitant treatment:

    • potent cytochrome P450 () inhibitors
    • drugs or herbal products that prolong the and known to increase the risk of Torsade de Pointes
  • Previous treatment with class I or class III anti-arrhythmic drugs (including sotalol) other than amiodarone if the anti-arrhythmic drug was taken less than one week before the day of screening (if taken more than one week before screening, the patient can be included)

Randomization

  • Bradycardia \< 50 bpm on the 12-lead ECG
  • History of, or current heart failure or left ventricular systolic dysfunction
  • Unstable hemodynamic conditions
  • Severe hepatic impairment
  • Mandatory contraindicated concomitant treatment:

    • potent cytochrome P450 (CYP3A4) inhibitors
    • drugs or herbal products that prolong the QT interval and known to increase the risk of Torsade de Pointes

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Group A

    Dronedarone 400 mg twice daily for 8 weeks starting from randomization. The last 2 months regimen of Amiodarone 200 mg/day is continued until randomization.

    Drug: Dronedarone

  • Experimental
    Group B

    Dronedarone 400 mg twice daily for 6 weeks starting 2 weeks after randomization. The last 2 months regimen of Amiodarone 200 mg/day is continued until randomization.

    Drug: Dronedarone

  • Experimental
    Group C

    Dronedarone 400 mg twice daily for 4 weeks starting 4 weeks after randomization. The last 2 months regimen of Amiodarone 200 mg/day is continued until randomization.

    Drug: Dronedarone

Interventions

  • Pharmaceutical form: tablet Route of administration: oral (together with meal) Dose regimen: 400 mg twice daily

    Also known as: Multaq®, SR33589

06

What researchers measure

Primary outcomes

  1. Plasma levels of dronedarone and its metabolite

    Time frame: At randomization (baseline), 3 hours after the first dose of dronedarone, after 1, 2 and 4 weeks of treatment with dronedarone (before dronedarone dose)

Secondary outcomes

  1. Plasma levels of amiodarone and its metabolite

    Time frame: At randomization (baseline), 3 hours after the first dose of dronedarone, after 1, 2 and 4 weeks of treatment with dronedarone (before dronedarone dose)

  2. Number of patients with AF recurrence

    Time frame: From randomization up to 60 days after

  3. Number of patients with Adverse Events of Special Interest (AESIs)

    Specific AESIs are: congestive Heart Failure (CHF), Interstitial lung disease , severe skin disorders, peripheral neuropathy including optic neuropathy and increase in alanine aminotransferase (ALT)

    Time frame: Up to 8 weeks after randomization

  4. Number of patients with symptomatic bradycardia (Heart Rate (HR) < 50 beats per minute at rest)

    Time frame: Up to 8 weeks after randomization

  5. Number of patients with symptomatic tachycardia (HR > 120 beats per minute at rest)

    Time frame: Up to 8 weeks after randomization

07

Study locations

40 sites
  • Investigational Site Number 170001
    Bogota, Colombia
  • Investigational Site Number 170002
    Bucaramanga, Colombia
  • Investigational Site Number 170003
    Cartagena, Colombia
  • Investigational Site Number 170006
    Cartagena, Colombia
  • Investigational Site Number 170007
    Floridablanca, Colombia
  • Investigational Site Number 170005
    Medellin, Colombia
  • Investigational Site Number 203005
    Brno, Czech Republic
  • Investigational Site Number 203003
    Kladno, 27280, Czech Republic
  • Investigational Site Number 203002
    Olomouc, Czech Republic
  • Investigational Site Number 203007
    Prachatice, 38301, Czech Republic
  • Investigational Site Number 203001
    Praha 2, 12808, Czech Republic
  • Investigational Site Number 203004
    Praha 9, 19000, Czech Republic
  • Investigational Site Number 203008
    Pribram, 26101, Czech Republic
  • Investigational Site Number 203006
    Sternberk, 78501, Czech Republic
  • Investigational Site Number 208-001
    Aarhus, 8000, Denmark
  • Investigational Site Number 208-002
    Copenhagen, 2400, Denmark
  • Investigational Site Number 208-003
    København S., 2300, Denmark
  • Investigational Site Number 250-004
    AMIENS Cedex 1, 80054, France
  • Investigational Site Number 250-005
    Boulogne Billancourt Cedex, 92104, France
  • Investigational Site Number 250-003
    Chambray Les Tours Cedex, 37171, France
  • Investigational Site Number 250-002
    GRENOBLE cedex, 38043, France
  • Investigational Site Number 250-001
    Montpellier, 34295, France
  • Investigational Site Number 250-006
    TOULOUSE Cedex 9, 31059, France
  • Investigational Site Number 276-001
    Bonn, 53105, Germany
  • Investigational Site Number 276-002
    Chemnitz, 09111, Germany
  • Investigational Site Number 276-005
    Hagen, 58095, Germany
  • Investigational Site Number 276-003
    Nürnberg, 90402, Germany
  • Investigational Site Number 276-004
    Wermsdorf, 04779, Germany
  • Investigational Site Number 484003
    Aguascalientes, 20020, Mexico
  • Investigational Site Number 484002
    Mexico, 11340, Mexico
  • Investigational Site Number 484001
    San Luis Potosi, 72244, Mexico
  • Investigational Site Number 484005
    San Luis Potosi, 78200, Mexico
  • Investigational Site Number 484004
    Torreon, 27000, Mexico
  • Investigational Site Number 484006
    Zapopan, 45200, Mexico
  • Investigational Site Number 724004
    Barakaldo, 48903, Spain
  • Investigational Site Number 724001
    Barcelona, 08036, Spain
  • Investigational Site Number 724005
    Hospitalet de Llobregat, 08907, Spain
  • Investigational Site Number 724002
    Madrid, 28046, Spain
  • Investigational Site Number 724003
    Málaga, 29010, Spain
  • Investigational Site Number 724006
    Valdemoro, 28342, Spain
08

References and documents

Publications

  • Naccarelli GV, Bhatt DL, Camm AJ, Le Heuzey JY, Lombardi F, Tamargo J, Martinez JM, Naditch-Brule L; ARTEMIS AF Investigators. Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies. J Cardiovasc Pharmacol Ther. 2020 Sep;25(5):425-437. doi: 10.1177/1074248420926874. Epub 2020 Jun 5. PubMed 32500725 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2010
First posted
Sep 10, 2010
Start
Oct 2010
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Last update
Jun 7, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01199081
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 10, 2010
Start date
Oct 2010
Primary completion
Apr 2012
Completion
Apr 2012
Last update
Jun 7, 2013

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronedarone

Start the discussion